| Alexis Savannah Marks, | |
|
School Of Nursing Cbx 063, Milledgeville, GA 31061 | |
| (478) 445-1076 | |
| Not Available |
| Full Name | Alexis Savannah Marks |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | School Of Nursing Cbx 063, Milledgeville, Georgia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609558998 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | RN295140 (Georgia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Alexis Savannah Marks, 195 Newton Ridge Dr, Covington, GA 30014 Ph: () - | Alexis Savannah Marks, School Of Nursing Cbx 063, Milledgeville, GA 31061 Ph: (478) 445-1076 |
News Archive
As scientists work to find new treatments for Pompe disease - the devastating genetic "villain" that drives the efforts of the main characters in the new film "Extraordinary Measures" - University of Florida researchers are hopeful that gene therapy will help patients in the late stages of the disease breathe on their own.
Innovaro, a comprehensive innovation solutions company, is pleased to announce that it has facilitated the completion of a licensing transaction between Trojan Technologies USA, a company recently formed by Verdant Ventures Advisors II, LLC, and Trojantec Ltd, a London and Cyprus based biopharmaceutical company.
Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.
Lorus Therapeutics Inc. today announced that the Food and Drug Administration completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), lymphomas and multiple myeloma.
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company's VB-111 program at the American Association for Cancer Research 102nd Annual Meeting.
› Verified 9 days ago
Mrs. Shelby Lynn Fulghum, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 235 Parks Memorial Building, Cbx 063, Milledgeville, GA 31061 Phone: 229-798-0816 | |
Lora Longino Elston, RNC, IBCLC Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 378 Black Springs Rd Ne, Milledgeville, GA 31061 Phone: 478-234-8012 | |
Hannah Snow Nolan, Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 231 W Hancock St, Milledgeville, GA 31061 Phone: 478-986-0822 | |
Mrs. Debra Menger Powelski, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 821 North Cobb Street, Milledgeville, GA 31061 Phone: 478-454-3750 | |
Suntana Ly, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 231 W Hancock St, Milledgeville, GA 31061 Phone: 478-455-1076 | |
Claire Brooks, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 231 West Hancock Street, Milledgeville, GA 31061 Phone: 478-445-5004 | |
Angelina Lynn Newman, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 196 Laying Farm Rd Se, Milledgeville, GA 31061 Phone: 478-414-2343 |